Wilex to acquire UCB's five preclinical oncology portfolio programmes

UCB Pharma S.A. (UCB) and Wilex AG, a company specialising in the development of drugs and diagnostic agents for cancer (Wilex), announced that they have agreed to enter into a strategic partnership.

The details can be read here.